The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

PhRMA members invested $58.8 billion in R&D in 2015

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA’s member companies invested an estimated $58.8 billion in research and development in 2015, up 10.3 percent from 2014, based on the 2016 PhRMA annual member survey published in the 2016 Biopharmaceutical Research Industry Profile.

According to PhRMA, the biopharmaceutical industry is the most research-intensive sector of the U.S. economy, investing on average six times more in R&D as a percentage of sales than all other manufacturing industries.

The sector also accounted for an estimated 17 percent of all U.S. business R&D spending, the largest share of R&D spending by U.S. businesses. From 2000 to 2015, more than 550 new medicines were approved by FDA, including a record 56 new medicines in 2015.

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Those of us who have devoted our careers to treating recalcitrant cancers know the heartbreak of walking alongside an individual facing an advanced diagnosis. We not only shoulder the clinical responsibility, but also the emotional weight that accompanies every step of that journey as each patient’s story becomes connected to our own.
By W. Kimryn Rathmell

At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer

If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.
By Sara Willa Ernst, Claire Marie Porter and Paul Goldberg

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

In a poignant keynote punctuated with anecdotes about grief, American Society of Clinical Oncology’s immediate past president Eric Small emphasized that the annual conference is not just about scientific discovery, but about a responsibility to translate discoveries into better outcomes for cancer patients globally. 
By Claire Marie Porter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account